Cyndi Lauper is back to star in another round of Novartis’ Cosentyx marketing. The '80s pop icon appears with two real-life patients in a new TV spot.
Pharma's big on disease awareness, but Allergan is going really big with its latest push: It’s aiming for a whole month dedicated to uterine fibroids.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Merck & Co. nabbed tentative FDA approval for its Lantus copy, Lusduna, which would be the second follow-on challenger to the Sanofi blockbuster.
Purdue, which has been fending off lawsuits over pain drug OxyContin in the U.S., may have to face off against Canada’s federal government.
Shire fought hard to stop it, but no dice: CSL has now launched its hereditary angioedema med Haegarda—and at a big discount, too.
Not only is Merck’s Keytruda still grabbing market share from Bristol-Myers Squibb archrival Opdivo, but it’s picked up the pace, too.
Gilead is out with a brand-new second-line hep C treatment—but the length of its dosing schedule could set the company back down the line, one analyst predicts.
The pharma industry’s reputation among patient groups in the U.S. has sunk to a recent low, and some are pointing to the country's leader as the reason.
What might Alexa do for diabetes patients? Serve as a mood-sensing coach, nutrition assistant and a sleuth that detects risky behaviors, for three.
It’s been just over six months since Biogen’s pricey Spinraza won FDA approval, and insurance coverage is looking better than some had expected.